Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (451-460 of 1,137) with videos related to

Pageof 114
Sort By:
Journal of the American College of Cardiology|June 17, 1998
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial InfarctionD A Morrow, N Rifai, E M Antman, et al.
Antisense & Nucleic Acid Drug Development|July 21, 1998
A comparison of guanosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formationW Wang, H J Chen, J Sun, et al.
JAMA Network Open|April 29, 2022
Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysisBahar Behrouzi, Deepak L Bhatt, Christopher P Cannon, et al.
American Heart Journal|June 24, 2010
Association of insurance status with inpatient treatment for coronary artery disease: findings from the Get With the Guidelines programMladen I Vidovich, Samip Vasaiwala, Christopher P Cannon, et al.
Journal of the American College of Cardiology|October 22, 2013
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38)Payal Kohli, Jacob A Udell, Sabina A Murphy, et al.
Diabetes, Obesity & Metabolism|February 17, 2017
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO IILawrence A Leiter, José Luis Zamorano, Maja Bujas-Bobanovic, et al.
Journal of the American College of Cardiology|February 17, 2000
Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudyD A Morrow, N Rifai, E M Antman, et al.
Journal of Thrombosis and Thrombolysis|October 6, 2007
Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16Benjamin A Olenchock, Stephen D Wiviott, Sabina A Murphy, et al.
The American Journal of Cardiology|August 25, 2004
Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy)C Michael Gibson, Kanwar P Singh, Sabina A Murphy, et al.
American Heart Journal|January 7, 2003
Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 RegistryMaria Cecilia Bahit, Christopher P Cannon, Elliott M Antman, et al.
Pageof 114

Showing results (451-460 of 1,137) with videos related to

Sort By:
Pageof 114
Journal of the American College of Cardiology|June 17, 1998
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial InfarctionD A Morrow, N Rifai, E M Antman, et al.
Antisense & Nucleic Acid Drug Development|July 21, 1998
A comparison of guanosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formationW Wang, H J Chen, J Sun, et al.
JAMA Network Open|April 29, 2022
Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysisBahar Behrouzi, Deepak L Bhatt, Christopher P Cannon, et al.
American Heart Journal|June 24, 2010
Association of insurance status with inpatient treatment for coronary artery disease: findings from the Get With the Guidelines programMladen I Vidovich, Samip Vasaiwala, Christopher P Cannon, et al.
Journal of the American College of Cardiology|October 22, 2013
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38)Payal Kohli, Jacob A Udell, Sabina A Murphy, et al.
Diabetes, Obesity & Metabolism|February 17, 2017
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO IILawrence A Leiter, José Luis Zamorano, Maja Bujas-Bobanovic, et al.
Journal of the American College of Cardiology|February 17, 2000
Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudyD A Morrow, N Rifai, E M Antman, et al.
Journal of Thrombosis and Thrombolysis|October 6, 2007
Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16Benjamin A Olenchock, Stephen D Wiviott, Sabina A Murphy, et al.
The American Journal of Cardiology|August 25, 2004
Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy)C Michael Gibson, Kanwar P Singh, Sabina A Murphy, et al.
American Heart Journal|January 7, 2003
Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 RegistryMaria Cecilia Bahit, Christopher P Cannon, Elliott M Antman, et al.
Pageof 114